diabetestalk.net

Sanofi Allstar Insulin Pen Price

Get To Know The Lantus® Solostar® Pen

Get To Know The Lantus® Solostar® Pen

Do not take Lantus® during episodes of low blood sugar or if you are allergic to insulin or any of the inactive ingredients in Lantus®. Do not share needles, insulin pens, or syringes with others. Do NOT reuse needles. Before starting Lantus®, tell your doctor about all your medical conditions, including if you have liver or kidney problems, if you are pregnant or planning to become pregnant or if you are breast-feeding or planning to breast-feed. Heart failure can occur if you are taking insulin together with certain medicines called TZDs (thiazolidinediones), even if you have never had heart failure or other heart problems. If you already have heart failure, it may get worse while you take TZDs with Lantus®. Your treatment with TZDs and Lantus® may need to be changed or stopped by your doctor if you have new or worsening heart failure. Tell your doctor if you have any new or worsening symptoms of heart failure, including: Sudden weight gain Tell your doctor about all the medications you take, including OTC medicines, vitamins, and supplements, including herbal supplements. Lantus® should be taken once a day at the same time every day. Test your blood sugar levels while using insulin, such as Lantus®. Do not make any changes to your dose or type of insulin without talking to your healthcare provider. Any change of insulin should be made cautiously and only under medical supervision. Do NOT dilute or mix Lantus® with any other insulin or solution. It will not work as intended and you may lose blood sugar control, which could be serious. Lantus® must only be used if the solution is clear and colorless with no particles visible. Always make sure you have the correct insulin before each injection. While using Lantus®, do not drive or operate heavy machinery until Continue reading >>

Sanofi Launches Reusable Insulin Pen

Sanofi Launches Reusable Insulin Pen

Oct 09, 2012 07:59 PM IST | Source: PTI Sanofi India Ltd today announced the launch of AllStar, its first indigenously manufactured reusable insulin pen Sanofi India Ltd today announced the launch of AllStar, its first indigenously manufactured reusable insulin pen. "We have launched AllStar, an indigenously manufactured reusable insulin pen at an affordable price of Rs 650 per unit. It is developed for Indian patients by Sanofi's medical device development team in Frankfurt," Sanofi India's managing director Shailesh Ayyangar told reporters here. AllStar is custom-made for patients in India and it will help improve both insulin initiation and compliance and bring ease and reassurance to the lives of Indian patents, giving them the convenience of international standards at an affordable price, he said.Incidentally, India has the second highest number of diabetics in the world estimated at 62 million. The company has also received enquiries from other emerging markets in Asia and Africa, Ayyangar said. Dr Shashank Joshi, President, Indian Academy of Diabetes, said, "in India, on an average, doctors prescribe insulin therapy to about one-third of their diabetes patients. Close to 75 percent patients are on vials with syringes and 25 percent on insulin pens.Insulin pens definitely offer greater advantage than vials and syringes in terms of ease of usage thereby increasing patient initiation and compliance to therapy, Joshi said. Continue reading >>

All Star Insulin Pen Price

All Star Insulin Pen Price

AllStar Reusable Insulin Delivery Device. Manufactured by Sanofi India Ltd. (Mumbai, India). World's leading marketplace. Allstar (lantus) Insulin Pen- Buy online at best prices with free delivery all over India. Check prices, choose and shop at Netmeds.com now and get up to 15% off. Our Guarantee. How can you get insulin at a cheaper price? Instructions for use AllStar Reusable insulin delivery device. The company is launching AllStar in emerging markets also after regulatory approvals. Lantus (insulin glargine) is a long-acting type of insulin. Find prescription medicine Allstar Reusable Insulin Pen(Device) and its top bio-equivalent substitutes / generic alternatives. The number in the dose window will return to "0" as you inject. Office timing: Mon - Sat 10:00 AM - 07:00 PM The following are the results of on-going survey on TabletWise.com for Allstar Insulin Pen. Drug information on brand Lantus 100iu (10ml Injection) (Insulin Glargine). Review all of the instructions before using your ... (insulin glargine injection) 300 Units/mL? Important Safety Information for Apidra (insulin glulisine [rDNA origin] injection) SoloSTAR Apidra SoloSTAR is a disposable prefilled insulin pen. Buy allstar reusable insulin pen 1 pen pack online at discounted price. 0 out of 2 users report Allstar Insulin Pen medicine to have side-effects. Find out its price,dose and the nearest pharmacy to buy it. CanadianInsulin.com will provide the lowest price for Lantus SoloSTAR Pens from Canada. visit 1mg.com to know price, benefits and product information of allstar reusable insulin pen. AllStar is a reusable pen for the injection of insulin. $115.95. You have just been prescribed Lantus (insu-lin glargine) or Apidra (insulin glulisine) in a ClikStar reusable insulin pen. 2 out of 2 users rep Continue reading >>

Initial Experience And Evaluation Of Reusable Insulin Pen Devices Among Patients With Diabetes In Emerging Countries

Initial Experience And Evaluation Of Reusable Insulin Pen Devices Among Patients With Diabetes In Emerging Countries

Initial Experience and Evaluation of Reusable Insulin Pen Devices Among Patients with Diabetes in Emerging Countries Institute for Children with Diabetes, R. Alvares Cabral, 529, Porto Alegre, RS 91350-250 Brazil The Research Partnership, Ltd., London, UK This article has been cited by other articles in PMC. Many individuals with type 2 diabetes in emerging countries are transitioning from vial-and-syringe insulin delivery to that of insulin pens (disposable or reusable). As with all insulin delivery methods, patient preferences and comfort are of utmost importance to optimize adherence to treatment. Patient-preferred characteristics for reusable insulin pens and barriers to appropriate injection, particularly in these regions, have not been widely reported in the clinical literature, highlighting a key information gap for clinicians considering these methods as part of a comprehensive diabetes management approach. Face-to-face interviews were conducted with people with type 1/2 diabetes, including insulin-nave and established insulin users. After moderator demonstration, participants were evaluated on their ability to perform a six-step process to inject a 10-unit dose into a pad with the AllStar (AS; Sanofi, Mumbai, India), HumaPen Ergo II (HE2; Eli Lilly, Indianapolis, USA), and NovoPen 4 (NP4; Novo Nordisk, Bagsvrd, Denmark) pens. Local pens were also tested in India, China and Brazil. A total of 503 people from India, Malaysia, Brazil, Egypt, and China participated. Participants completed the six-step process in an average, 23min per pen. Participants ranked ease of overall use and ease of self-injection and dialing/reading dose as most important features for new insulin pens. When using the pens, the most difficult step was priming/safety testing, with 712% faili Continue reading >>

How To Use The Lantus® Solostar® Pen

How To Use The Lantus® Solostar® Pen

Please check the leaflet for the insulin for complete instructions on how to store SoloSTAR®. If your SoloSTAR® is in cool storage, take it out 1 to 2 hours before you inject to allow it to warm up. Cold insulin is more painful to inject. Keep SoloSTAR® out of the reach and sight of children. Keep your SoloSTAR® in cool storage (36°F–46°F [2°C–8°C]) until first use. Do not allow it to freeze. Do not put it next to the freezer compartment of your refrigerator, or next to a freezer pack. Once you take your SoloSTAR® out of cool storage, for use or as a spare, you can use it for up to 28 days. During this time it can be safely kept at room temperature up to 86°F (30°C). Do not use it after this time. SoloSTAR® in use must not be stored in a refrigerator. Do not use SoloSTAR® after the expiration date printed on the label of the pen or on the carton. Protect SoloSTAR® from light. Discard your used SoloSTAR® as required by your local authorities. Protect your SoloSTAR® from dust and dirt. You can clean the outside of your SoloSTAR® by wiping it with a damp cloth. Do not soak, wash, or lubricate the pen as this may damage it. Your SoloSTAR® is designed to work accurately and safely. It should be handled with care. Avoid situations where SoloSTAR® might be damaged. If you are concerned that your SoloSTAR® may be damaged, use a new one. Continue reading >>

Sanofi India Launches Allstar - A Reusable Insulin Pen | Drugsupdate India

Sanofi India Launches Allstar - A Reusable Insulin Pen | Drugsupdate India

Sanofi India Launches AllStar - A Reusable Insulin Pen The Sanofi India Group announced the launching of AllStar in India, an indigenously developed, reusable insulin pen. The device is tailored according to Indian consumers, and the device is for anyone who is using Sanofi insulin products, as recommended by physicians. The device is designed with unique ten-in-one features that meet strict ISO standards. After the regulatory nod, the product will be available in Indian markets at an affordable price tag of Rs. 650. According to Dr. Sailesh Ayyangar, Managing Director and VP of Group Sanofi, South Asian Region, the company is a forerunner in diabetic research and drug development and AllStar is the best example for the companys commitment to patients. The R&D researchers worked for more than three years and indigenously developed a reusable tool. The devising of AllStar was a first step in the manufacturing process of Sanofi India and AllStar technology will be innovatively used in the other devices, he said. The introduction of AllStar in the Indian market was a notable landmark in Sanofi Indias diabetes research and showed the companys focus on diabetes research. The companys newer trends and geographical-specific approach lead to the success that meet the Indian needs, he added. When commenting about the device launching, Dr. Volker Korger, Head of Diabetes Devices Product, Frankfurt said the injection pen is designed by an innovative technology with attractive design and style. The research team from Germany and UK that designed Solostar, devised AllStar, in compliance with Indias requirement. The hardware was designed in Germany, and some specific tools for accuracy were designed by Taiwan researchers. With the final design, the devices are being manufactured in Continue reading >>

Allstar Re-usable Insulin Pen

Allstar Re-usable Insulin Pen

In October 2012 The French-German Sanofi Group announced in Paris the launch by Sanofi India Limited of AllStar, the first Indian-manufactured, re-usable insulin pen. This is the first such device to be manufactured by a global company in India. Developed especially for patients in emerging markets, AllStar is for use by patients using Sanofis insulin portfolio, and also for insulin-naive patients who are starting to use insulin. The AllStar re-usable insulin pen conforms to ISO (International Organization for Standardization) standards and is equipped with state-of-the art features. But of course the story starts much earlier with the initial identification of a need in an emerging market for a re-usable device that could be built in a low-cost environment yet still conform to internationally recognised standards. Sanofi in Frankfurt collaborated once again with DCA Design in Warwick to develop the device with as few a number of components as possible for ease of assembly. Along with German, Swiss, Indian and Taiwanese suppliers Clamason was invited to assist in the development program for two precision pressed metal springs within the device, these components ensure that each time the insulin vial is replaced it sits correctly. DCA and Clamason worked closely together, initially starting with one highly complex component which folded into position, however this eventually became two individual parts for ease of manufacture. A series of prototype tools were made which developed into production tooling followed by validation and the addition of two more UK companies to ensure that the components & final assembly in India all conform. Sanofi has always been at the forefront of diabetes research and development. AllStar is a testament to Sanofis patient-centric approach Continue reading >>

Sanofi Launches Re-usable Insulin Pen Priced Rs 650 - Business Line

Sanofi Launches Re-usable Insulin Pen Priced Rs 650 - Business Line

Sanofi launches re-usable insulin pen priced Rs 650 Volker Korger (right), Director-Diabetes Device Projects Global Medical Device Development, Sanofi Germany; Shailesh Ayyangar, Managing Director-India & Vice-President - South Asia, Group Sanofi; and Shashank Joshi, Consultant Endocrinologist at Lilavati Hospital, at a press conference in Mumbai on Tuesday. Shashi Ashiwal - Business Line The Indian-arm of French company Sanofi has brought out a re-usable insulin delivery pen completely Made-in-India. It took three years to develop the indigenously made device sold under the AllStar brand name, designed on the feed back of people in India, said Shailesh Ayyangar, Sanofi Indias Managing Director and Vice-President. Priced at Rs 650 per pen, the device is pegged at about 20 per cent less than other similar products in the market, he added. A person with diabetes could use the pen-shaped device by fitting it with a cartridge of Sanofis insulin and injecting themselves. There are queries for AllStar from South-East Asian and African markets, he said, and a regulatory pathway is being worked out to sell in these markets. India is estimated to have about 64 million people with diabetes. The product has been designed in-keeping with the specific needs of the local market, he said. The device will be made in Gujarat. For the Rs 2,000-crore Sanofi India, about Rs 400 crore comes from its diabetes portfolio comprising orally consumed drugs and insulin. Outlining the features of the device, Volker Korger, Sanofis Head - Diabetes Device Projects (Frankfurt), said the device was the slimmest, shortest and lightest of pens available in India. The device is the outcome of a multi-country venture, including Germany, the United Kingdom, Taiwan and India, he said. One of the key feature Continue reading >>

Sanofi To Launch State-of-the Art, Reusable Insulin Pen Allstar Inindia

Sanofi To Launch State-of-the Art, Reusable Insulin Pen Allstar Inindia

Sanofi to Launch State-of-the Art, Reusable Insulin Pen AllStar inIndia - Sanofi shows its continued commitment to patients needs in emerging markets and improves access to innovative, affordable devices Paris, France October 9, 2012 Sanofi (EURONEXT: SAN and NYSE: SNY) announced today the launch by Sanofi India Limited of AllStar, the first Indian-manufactured, re-usable insulin pen, manufactured by a global company in India. Developed especially for patients in emerging markets, AllStar is indicated for use of insulinized patients using Sanofis insulin portfolio, and also for insulin-naive patients who are starting to use insulin. The AllStar re-usable insulin pen conforms to ISO (International Organization for Standardization) standards and is equipped with state-of-theart features. AllStar will be commercially launched in India this October. The launch of AllStar is a significant milestone emblematic of Sanofis leadership in addressing the needs of people with diabetes in India. It highlights Sanofis commitment to diabetes and emerging markets and its regionalized approach to finding solutions that are adapted to local market needs. Going forward, Sanofi intends to make AllStar accessible to other emerging markets. Sanofi has always been at the forefront of diabetes research and development. AllStar is a testament to Sanofis patient-centric approach and leverages our strong commitment to embracing innovation coming from emerging markets like India, says Pierre Chancel, Senior Vice President, Global Diabetes, Sanofi. Sanofi Indias manufacturing its own re-usable insulin device is the results of three years of exemplary team work with the sole purpose of offering a device that would match the needs of people with diabetes in India and other emerging markets. AllStar Continue reading >>

More in insulin